Murrieta Genomics has been conceived and specifically built to provide Next Generation Sequencing services,  training, education, and business incubation. Next generation sequencing is a disruptive genomics technology that allows scientists to sequence and assemble billions of short DNA reads. This technology is used for applications including human whole genome sequencing, whole exome sequencing, targeted sequencing, and expression profiling (a.k.a. RNA-Seq).

Genomic information has been instrumental in identifying inherited disorders, characterizing the mutations that drive cancer progression, and tracking disease outbreaks. Rapidly dropping sequencing costs and the ability to produce large volumes of data with today’s sequencers make whole-genome sequencing a powerful tool for genomics research.

Sequencing the genome is an important step towards understanding it, but the path from sequencing to effective clinical applications is complex and challenging. Discovery, development and application of genome-based diagnostic and prognostic applications require both a science strategy and an implementation strategy for successful commercialization.

The goal of the Murrieta Genomics incubator is to foster the development of new precision medicine companies using the latest state of the art genomic sequencing and artificial intelligence technologies.

We want to be a home for the rapidly evolving field of precision medicine - an evidence-based approach to the care of people and patients that uses innovative tools and data science to customize disease prevention, detection, and individualize treatment to improve the effectiveness and quality of care.